Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.

Publisher: Taylor & Francis Country of Publication: England NLM ID: 101271248 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8409 (Electronic) Linking ISSN: 1744666X NLM ISO Abbreviation: Expert Rev Clin Immunol Subsets: MEDLINE

Publication: 2015- : Abingdon, Oxford : Taylor & Francis
Original Publication: London, UK : Future Drugs Ltd., 2005-

Immune Checkpoint Inhibitors*/adverse effects ; Immune Checkpoint Inhibitors*/therapeutic use ; Neoplasms*/immunology ; Neoplasms*/drug therapy ; Neoplasms*/therapy ; Immunotherapy*/adverse effects ; Immunotherapy*/methods ; Rheumatic Diseases*/drug therapy ; Rheumatic Diseases*/immunology; Humans

Introduction: The advent of immune checkpoint inhibitors (ICIs) in cancer treatment has marked a transformative era, albeit tempered by immune-related adverse events (irAEs), including those impacting the musculoskeletal system. The lack of precise epidemiologic data on rheumatic irAEs is attributed to factors such as potential underrecognition, underreporting in clinical trials, and the tendency to overlook manifestations without immediate life-threatening implications, further complicating the determination of accurate incidence rates, while the complete understanding of the mechanisms driving rheumatic irAEs remains elusive.
Areas Covered: This literature review comprehensively examines rheumatic irAEs in cancer patients undergoing ICI therapy, encompassing epidemiology, risk factors, mechanisms, clinical manifestations, and current management guidance for prevalent conditions such as inflammatory arthritis, polymyalgia rheumatica, and myositis. Less frequent rheumatic and musculoskeletal irAEs are also explored, alongside insights into ongoing clinical trials testing therapeutic and preventive strategies for irAEs. A thorough literature search on Medline and the National Cancer Institute Clinical Trials Database was conducted up to October 2023 to compile relevant information.
Expert Opinion: In light of the evolving landscape of cancer immunotherapy, there is a compelling need for prospective longitudinal studies to enhance understanding and inform clinical management strategies for rheumatic irAEs.

J Immunother Cancer. 2023 Jun;11(6):. (PMID: 37328287)
Neurohospitalist. 2011 Jan;1(1):16-22. (PMID: 23983833)
N Engl J Med. 2022 Jan 6;386(1):24-34. (PMID: 34986285)
Neurol Neuroimmunol Neuroinflamm. 2018 Dec 24;6(2):e535. (PMID: 30697585)
J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33219094)
Semin Arthritis Rheum. 2019 Feb;48(4):736-740. (PMID: 29909921)
Mediterr J Rheumatol. 2021 Sep 30;32(3):218-226. (PMID: 34964025)
Cancer Sci. 2016 Jul;107(7):1055-8. (PMID: 27420474)
Oncologist. 2019 May;24(5):584-588. (PMID: 30819785)
Cancer Immunol Immunother. 2021 Aug;70(8):2197-2207. (PMID: 33471137)
Ann Rheum Dis. 2022 Feb;81(2):e32. (PMID: 32066555)
Open Access Rheumatol. 2021 Jul 02;13:177-190. (PMID: 34239333)
Arthritis Rheumatol. 2021 May;73(5):866-874. (PMID: 33258544)
Cancer Immunol Immunother. 2021 Jan;70(1):89-100. (PMID: 32648164)
Nat Med. 2021 Aug;27(8):1432-1441. (PMID: 34239137)
Arthritis Rheumatol. 2019 Nov;71(11):1823. (PMID: 31297971)
J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. (PMID: 35390769)
J Immunother Cancer. 2021 Jul;9(7):. (PMID: 34233963)
Ann Rheum Dis. 2022 Aug 3;:. (PMID: 35922125)
Cancer Immunol Immunother. 2021 Jul;70(7):1939-1949. (PMID: 33409738)
Front Immunol. 2021 Dec 06;12:803410. (PMID: 34938300)
Intern Med. 2019 Oct 1;58(19):2839-2843. (PMID: 31243239)
Eur J Cancer. 2019 Jan;106:12-23. (PMID: 30453170)
Clin Cancer Res. 2021 Sep 15;27(18):5131-5140. (PMID: 34244291)
Rheumatology (Oxford). 2019 Mar 1;58(3):476-480. (PMID: 30508191)
BMJ Case Rep. 2021 Feb 4;14(2):. (PMID: 33541985)
Cancers (Basel). 2023 May 30;15(11):. (PMID: 37296947)
Curr Opin Rheumatol. 2019 May;31(3):293-299. (PMID: 30870217)
Am J Pathol. 2016 Dec;186(12):3225-3235. (PMID: 27750046)
PLoS One. 2016 Jul 29;11(7):e0160221. (PMID: 27472273)
Front Oncol. 2022 Oct 31;12:1010660. (PMID: 36387148)
Oral Dis. 2022 Nov;28(8):2083-2092. (PMID: 34379884)
Melanoma Res. 2017 Apr;27(2):171-173. (PMID: 28099367)
Nat Rev Rheumatol. 2018 Oct;14(10):569-579. (PMID: 30171203)
Front Immunol. 2023 Feb 02;14:988365. (PMID: 36817431)
J Immunother Cancer. 2022 Sep;10(9):. (PMID: 36096534)
Eur J Cancer. 2021 Nov;157:383-390. (PMID: 34571335)
Best Pract Res Clin Rheumatol. 2022 Dec;36(4):101805. (PMID: 36539321)
Immunol Rev. 2008 Aug;224:166-82. (PMID: 18759926)
Front Immunol. 2022 Jan 28;13:807050. (PMID: 35154124)
Ann Rheum Dis. 2022 Oct;81(10):e210. (PMID: 32241799)
Arthritis Rheumatol. 2016 Feb;68(2):556-7. (PMID: 26314277)
Front Med (Lausanne). 2022 Nov 15;9:950801. (PMID: 36457566)
Front Oncol. 2022 Dec 08;12:1053370. (PMID: 36568231)
J Immunother Cancer. 2019 Nov 21;7(1):319. (PMID: 31753014)
BMC Rheumatol. 2022 Nov 8;6(1):64. (PMID: 36345032)
J Autoimmun. 2019 Jun;100:105-113. (PMID: 30862448)
J Clin Oncol. 2022 May 1;40(13):1474-1486. (PMID: 35119908)
N Engl J Med. 2016 Nov 03;375(18):1749-1755. (PMID: 27806233)
Circulation. 2018 Aug 14;138(7):743-745. (PMID: 30359135)
J Immunother Cancer. 2018 Oct 11;6(1):104. (PMID: 30305172)
Front Immunol. 2023 Jun 26;14:1212432. (PMID: 37435072)
J Neurol Sci. 2023 Jan 15;444:120528. (PMID: 36565689)
Case Rep Hematol. 2018 Jan 11;2018:3106852. (PMID: 29581905)
Semin Arthritis Rheum. 2018 Dec;48(3):553-557. (PMID: 29573850)
J Clin Oncol. 2018 Oct 1;36(28):2872-2878. (PMID: 30125216)
ACR Open Rheumatol. 2022 Jan;4(1):83-84. (PMID: 34757698)
Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. (PMID: 32246128)
J Immunother Cancer. 2016 Sep 20;4:55. (PMID: 27660709)
Semin Arthritis Rheum. 2023 Feb;58:152110. (PMID: 36372016)
Int J Clin Pharm. 2022 Jun;44(3):689-697. (PMID: 35449347)
J Immunother Cancer. 2020 Jun;8(1):. (PMID: 32571993)
RMD Open. 2023 Jun;9(2):. (PMID: 37355249)
Arthritis Rheumatol. 2022 Mar;74(3):527-540. (PMID: 34397169)
Front Pharmacol. 2022 Mar 25;13:803706. (PMID: 35401222)
J Immunother Cancer. 2021 Sep;9(9):. (PMID: 34526389)
Nat Rev Rheumatol. 2022 Mar;18(3):133-145. (PMID: 34987201)
Ann Transl Med. 2021 Jun;9(12):1033. (PMID: 34277833)
J Clin Oncol. 2021 Dec 20;39(36):4073-4126. (PMID: 34724392)
Cell. 2015 Apr 9;161(2):205-14. (PMID: 25860605)
Rheumatology (Oxford). 2018 Apr 1;57(4):760-762. (PMID: 29342300)
Cancer. 2018 Sep 15;124(18):3706-3714. (PMID: 29975414)
J Cancer Res Clin Oncol. 2023 Aug;149(9):6341-6350. (PMID: 36752908)
Eur J Cancer. 2021 Nov;158:208-216. (PMID: 34452793)
J Immunother Cancer. 2018 Jun 5;6(1):49. (PMID: 29871698)
Clin Immunol. 2005 May;115(2):184-91. (PMID: 15885642)
Sci Immunol. 2023 Jul 28;8(85):eadd1591. (PMID: 37506196)
Intern Med. 2020 Feb 15;59(4):597-598. (PMID: 31666471)
J Clin Rheumatol. 2022 Mar 1;28(2):e498-e505. (PMID: 34371516)
Ann Intern Med. 2018 Jan 16;168(2):121-130. (PMID: 29297009)
J Clin Rheumatol. 2022 Oct 1;28(7):367-373. (PMID: 35696731)
Front Immunol. 2022 Sep 08;13:987568. (PMID: 36159840)
Nat Commun. 2022 Apr 12;13(1):1970. (PMID: 35413951)
RMD Open. 2019 Apr 25;5(1):e000906. (PMID: 31168414)
Cancers (Basel). 2022 Feb 04;14(3):. (PMID: 35159059)
Neurology. 2018 Sep 4;91(10):e985-e994. (PMID: 30089619)
Eur J Intern Med. 2022 Sep;103:95-99. (PMID: 35821192)
Cancer Immunol Res. 2019 Jan;7(1):6-11. (PMID: 30425107)
J Immunol. 2012 Oct 1;189(7):3759-66. (PMID: 22956585)
Ann Rheum Dis. 2017 Oct;76(10):1747-1750. (PMID: 28600350)
Front Pharmacol. 2022 May 12;13:884776. (PMID: 35645839)
Front Oncol. 2021 Feb 11;10:585311. (PMID: 33643899)
RMD Open. 2022 Sep;8(2):. (PMID: 36096522)
J Oncol Pharm Pract. 2022 Apr;28(3):750-753. (PMID: 34964671)
J Immunother Cancer. 2023 Mar;11(3):. (PMID: 37001909)
BMJ Open Gastroenterol. 2022 Dec;9(1):. (PMID: 36581371)
J Rheumatol. 2007 Jun;34(6):1401-14. (PMID: 17552067)
Rheumatology (Oxford). 2020 May 1;59(5):1041-1050. (PMID: 32344435)
Autoimmun Rev. 2023 Aug;22(8):103375. (PMID: 37321468)
Ann Rheum Dis. 2023 Jul;82(7):920-926. (PMID: 37019614)
Immunol Rev. 2010 Jul;236:219-42. (PMID: 20636820)
N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431)
Intern Med. 2020 Apr 15;59(8):1075-1080. (PMID: 32009093)
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii40-vii48. (PMID: 31816084)
Immunotherapy. 2017 Jan;9(1):5-8. (PMID: 28000525)
J Immunother Cancer. 2021 Jul;9(7):. (PMID: 34226279)
Cancer Discov. 2023 May 4;13(5):1100-1115. (PMID: 36815259)
Ann Rheum Dis. 2020 Mar;79(3):332-338. (PMID: 31540935)
Ann Rheum Dis. 2019 Jan;78(1):150-152. (PMID: 30185415)
BMC Rheumatol. 2022 Sep 27;6(1):71. (PMID: 36163193)
Ann Rheum Dis. 2021 Jan;80(1):36-48. (PMID: 32327425)
Cancer Cell. 2022 May 9;40(5):509-523.e6. (PMID: 35537412)
J Clin Rheumatol. 2021 Dec 1;27(8):e317-e322. (PMID: 32345841)
Lancet Oncol. 2017 May;18(5):599-610. (PMID: 28373005)
J Clin Med. 2023 Jul 06;12(13):. (PMID: 37445562)
Biomed Pharmacother. 2022 Apr;148:112687. (PMID: 35228067)
Curr Cardiol Rep. 2021 Jul 1;23(8):98. (PMID: 34196833)
Science. 2018 Mar 23;359(6382):1350-1355. (PMID: 29567705)
ACR Open Rheumatol. 2019 Jun 12;1(5):303-307. (PMID: 31777806)
JAMA Oncol. 2019 Jul 01;5(7):1043-1047. (PMID: 31021392)
Oncologist. 2023 May 8;28(5):440-448. (PMID: 36595378)
Pharmaceuticals (Basel). 2023 Feb 08;16(2):. (PMID: 37259404)
Ann Rheum Dis. 2019 Jul;78(7):e67. (PMID: 29858173)
N Engl J Med. 2016 Sep 1;375(9):819-29. (PMID: 27433843)
Ann Rheum Dis. 2019 Jul;78(7):e68. (PMID: 29724725)
N Engl J Med. 2009 Jul 9;361(2):211-2. (PMID: 19587352)
Neurology. 2017 Sep 12;89(11):1127-1134. (PMID: 28821685)
J Immunother Cancer. 2021 Jun;9(6):. (PMID: 34172516)
Clin Rheumatol. 2018 Sep;37(9):2579-2584. (PMID: 29923081)
Lancet Oncol. 2018 Dec;19(12):1579-1589. (PMID: 30442497)
Science. 2015 Apr 3;348(6230):56-61. (PMID: 25838373)
Jpn J Clin Oncol. 2024 Apr 6;54(4):365-375. (PMID: 38183211)
J Bone Oncol. 2022 Oct 28;37:100459. (PMID: 36338920)
Eur J Cancer. 2020 Mar;128:17-26. (PMID: 32109847)

K01 AI163412 United States AI NIAID NIH HHS; P50 CA221703 United States CA NCI NIH HHS; R01 AR078484 United States AR NIAMS NIH HHS

Keywords: Cancer; immune checkpoint inhibitors; immune-related adverse events (irAEs); inflammatory arthritis; myositis; polymyalgia rheumatica; rheumatic diseases

0 (Immune Checkpoint Inhibitors)

Date Created: 20240224 Date Completed: 20240725 Latest Revision: 20241005

20241005

PMC11449381

10.1080/1744666X.2024.2323966

38400840